Fresenius Medical Care AG & Co. (Pref) (FME) PT Set at €95.40 by J P Morgan Chase & Co

Fresenius Medical Care AG & Co. (Pref) (ETR:FME) has been assigned a €95.40 ($112.24) price objective by research analysts at J P Morgan Chase & Co in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the stock. J P Morgan Chase & Co’s price target points to a potential upside of 14.66% from the stock’s previous close.

A number of other equities analysts also recently issued reports on FME. Goldman Sachs Group, Inc. (The) set a €97.00 ($114.12) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a research note on Monday, October 30th. Deutsche Bank AG set a €84.00 ($98.82) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. Commerzbank Ag set a €88.00 ($103.53) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “neutral” rating in a research note on Monday, August 7th. Kepler Capital Markets set a €95.00 ($111.76) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Finally, Berenberg Bank set a €92.10 ($108.35) price target on Fresenius Medical Care AG & Co. (Pref) and gave the stock a “buy” rating in a research note on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company’s stock. Fresenius Medical Care AG & Co. (Pref) currently has a consensus rating of “Hold” and an average price target of €89.12 ($104.84).

Fresenius Medical Care AG & Co. (ETR:FME) traded up €0.18 ($0.21) during mid-day trading on Thursday, hitting €83.20 ($97.88). The stock had a trading volume of 656,887 shares.

TRADEMARK VIOLATION WARNING: “Fresenius Medical Care AG & Co. (Pref) (FME) PT Set at €95.40 by J P Morgan Chase & Co” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.com-unik.info/2017/11/04/fresenius-medical-care-ag-95-40-by-j-p-morgan-chase-co-2.html.

Fresenius Medical Care AG & Co. (Pref) Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

What are top analysts saying about Fresenius Medical Care AG & Co. (Pref)? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fresenius Medical Care AG & Co. (Pref) and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit